Responsibility is one incentive when retail investors seek investments. Pharmaceuticals and healthcare is one of the most interesting sectors.
Research and development are Orion's strengths, and the company will continue to invest in them. The target is to increase net sales 1.5-fold by 2025.
Orion published Interim Report for January-September 2019 on Wednesday 23 October 2019.
Orion's Capital Markets Day was held on Wednesday 22 May 2019.
Information and instructions for shareholders who have shares on joint account.
Impact of Darolutamide on Pain and Quality of Life in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer (nmCRPC) at ASCO taking place in Chicago.
8 Mar 2019 I Marketing authorization application has been submitted to EMA. The rolling submission to the FDA in the U.S. was recently completed and the application has also been submitted in the MHLW in Japan.
The 2019 Annual General Meeting was held on 26 March 2019 in Helsinki. Read more here.
Information about the price development of Orion's A and B shares. Also available a list of analysts covering Orion and the latest consensus estimate.
Monthly updated list of Orion's major shareholders by votes.
Orion Corporation has been included in the globally recognised FTSE4Good Index.
